Physician profile
Roberto Zambon
NPI 1326147778
$5,943.13
in general payments reported to CMS, 2019-2025
22 companies · $19.95 in 2025
The $19.95 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $634 · 2021: $739 · 2022: $1,163 · 2023: $1,656 · 2024: $592 · 2025: $19.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,196.09 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Gilead Sciences, INC. | $1,079.48 | 2019-2025 | Biktarvy |
| Glaxosmithkline, LLC. | $639.46 | 2020-2023 | |
| Novo Nordisk INC | $465.44 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $317.72 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.14 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $263.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $232.45 | 2022-2024 | Eliquis, Camzyos |
| Lilly USA, LLC | $230.75 | 2019-2024 | Jardiance, Emgality |
| Abbott Laboratories | $227.18 | 2022 | |
| Amgen INC. | $224.75 | 2023-2024 | Repatha, Otezla |
| Horizon Therapeutics Plc | $201.63 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $114.96 | 2019-2023 | |
| Pfizer INC. | $100.01 | 2022-2023 | |
| Abbvie INC. | $69.12 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $60.17 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $53.17 | 2019-2021 | |
| Dexcom, INC. | $50.72 | 2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $40.88 | 2021-2022 | |
| Exact Sciences Corporation | $22.57 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $20.19 | 2019 | |
| Seqirus USA INC | $19.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Zambon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.